Opus Genetics (IRD) Q2 2026 earnings summary

Executive summary

• Advanced a pipeline of gene therapies for inherited retinal diseases (IRDs) and a small molecule ophthalmic therapy, with one FDA-approved product (RYZUMVI) generating royalties through a partnership with Viatris.

• Five gene therapy programs progressed, with key clinical data readouts expected in late 2026 and 2027, including completed enrollment in the pivotal LCA5 trial and dosing to begin Q4 2026.

• Significant progress in clinical development, including FDA designations, acceptance into rare disease programs, and completion of key enrollment milestones.

• Cash runway projected into 2029, supporting multiple clinical milestones and potential Priority Review Voucher opportunities.

Financial highlights

• License and collaborations revenue was $0.8M for Q2 2026, down from $2.9M in Q2 2025, and $2.9M for the six months ended June 30, 2026, down from $7.3M in the prior year period, mainly due to lower reimbursed R&D services.

• Net loss was $8.1M for Q2 2026 (vs. $7.4M in Q2 2025) and $73.6M for the six months ended June 30, 2026 (vs. $15.6M in 2025), driven by higher R&D expenses and a $44.2M non-cash warrant liability expense.

• Research and development expenses increased to $11.2M in Q2 2026 (from $6.0M), mainly due to expanded IRD program activities and increased manufacturing and clinical costs.

• Cash and cash equivalents were $88.8M as of June 30, 2026.

• G&A expenses were $6.0M, up slightly from $5.8M year-over-year.

Outlook and guidance

• Cash runway expected to fund operations for at least the next 12 months and projected into 2029, excluding potential warrant or milestone proceeds.

• Anticipates continued increase in expenses as clinical and nonclinical programs progress, with future revenue dependent on regulatory approvals and commercialization of pipeline assets.

• OPGX-BEST1 Cohort 1 topline data expected in September 2026; LCA5 trial dosing to start Q4 2026 with topline data by end of 2027; RDH12, MERTK, and RHO programs to enter clinical testing between Q4 2026 and H2 2027.

• Additional non-dilutive funding of up to $120M available through a note purchase agreement, subject to milestones and conditions.